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1. INTRODUCTION: 
Simvastatin belongs to the statin drug family, the 
members of which are used as cholesterol-lowering 
agents for patients with hypercholesterolemia. This 
semisynthetic drug (Fig. 1) exhibits a very important 
hepatic ﬁrst-pass metabolism by inhibiting 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA) and 
reduces low-density lipoproteins. Several methods can be 
employed in separation, purification and determination 
of these compounds1. The aim of our work is to develop 
simple, easy, cost effective and isocratic method for 
quantifying the Simvastatin after extraction from 
biological samples. 
 
Figure 1: Structure of Simvastatin. 
2. AIMS AND OBJECTIVES:  
1. Preparation of standard solutions of drug and internal 
standard.  
2. Recording chromatograms of the prepared standard 
solutions.  
3. Method development and validation of RP-HPLC 
method for quantification of Simvastatin. 
3. MATERIALS AND METHODS
2-7
: 
3.1. Instrumentation: 
HPLC method was performed using isocratic Shimadzu 
LC 10AD Pump with Shimadzu SPD 10 UV Detector 
operated by using Inspire C18 (250 x 4.5 mm, 5 µm) 
column with 20µL rheodyne injection volume. 
3.2. Reagents and Chemicals: 
Acetonitrile, Water and Glacial acetic acid were of 
HPLC grade obtained from Finar Chemicals 
(Ahmedabad, India). Simvastatin and Lovastatin were 
procured from Aurobindo Pharma ltd., and Lupin ltd., 
respectively as gift samples. 
3.3. Mobile phase: 
The mobile phase consists of acetonitrile and 0.1% 
glacial acetic acid in the ratio of 80:20 % v/v which was 
filtered through 0.45µ membrane filter and degassed 
before use and pumped into column at a flow rate of 1 
ml/min. The detection wavelength was set to 240 nm and 
the total run time was 15 min. 
 
* Corresponding author: 
Raghuram Reddy Adidala 
Head, Analysis Division, Synapse Life Sciences,  
Warangal, A.P., India. 506001. 
Contact number- +91-9949783347 
Email ID: - raghukpl@yahoo.com
ABSTRACT: 
Simvastatin is a potent competitive inhibitor of 3hydroxy-3-methylglutaryl coenzyme A reductase, which is a rate-limiting 
enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production due to the induction of 
hepatic LDL receptors, it increases breakdown of LDL cholesterol.  We have established a sensitive and accurate High 
performance liquid chromatographic method for determination of Simvastatin as per the ICH guidelines using specificity, 
linearity, limit of detection, limit of quantification, Precision and accuracy. Chromatography was performed with an analytical 
Inspire C18 column (250 mm x 2.0 mm, 5 µm), Shimadzu HPLC model with LC 10AD HPLC Pump and SPD 10A HPLC UV-
Detector, and using acetonitrile: 0.1% glacial acetic acid (80: 20 % v/v) as the mobile phase. The linearity of Simvastatin is 
0.999 over a concentration range of 0.1 to 10 µg/ml. Interday and intraday variability was < 10%.  
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3.4. Standard Solutions: 
Primary stock solutions of Simvastatin and Lovastatin 
(Internal standard) were prepared in methanol at a 
concentration of 1 mg/ml and stored at -200 C.  
3.4.1. Standard Solutions: 
From 1mg/ml solution of Simvastatin is pipetted out and 
diluted to different concentrations to obtain final 
concentrations of 0.1, 0.25, 0.5, 1, 2.5, 5 and 10 µg/ml 
and add 0.1 µg/ml of internal standard in common to all 
final concentrations. 
3.5. Method Validation
8-11
: 
Specificity, Linearity, Limit of Detection, Limit of 
Quantification, Precision and Accuracy was determined 
for the developed method.  
a. Specificity: 
The specificity method was used to determine any 
interference in the chromatogram during the retention 
time of both Simvastatin and Lovastatin (Internal 
standard). 
 
b. Linearity: 
The developed method was used for determining the 
linearity of Simvastatin ranging from the concentrations 
of 0.1 µg/ml to 10 µg/ml. Calibration curves were plotted 
by taking Peak area of Simvastatin on Y-axis and 
Concentration of corresponding Simvastatin on X-axis. 
The linearity was evaluated by linear regression analysis 
using least square method. The linearity was accepted if 
the r2 was greater than 0.99. 
 
c. LOD & LOQ Determination: 
Lower limit of detection and lower limit of quantification 
were determined by using the parameters of standard 
error of estimate and slope calculated from linearity data 
of Simvastatin.  
 
d. Precision and Accuracy: 
In order to assess the intra- and inter-day precision and 
accuracy, Simvastatin at low (40ng/ml), medium (400 
ng/ml) and high (4000 ng/ml) concentrations were 
prepared as described above. The intra-day precision of 
the assay was assessed by calculating the coefficient of 
variation (CV) for the analysis of samples in three 
replicates. And inter-day precision was determined by 
the analysis of samples on three consecutive days. 
Accuracy was calculated by comparing the measured 
values and the true values and expressed in percent.  
 
4. RESULTS AND DISCUSSION: 
4.1 Specificity:  
Chromatograms of Simvastatin and I.S. (Lovastatin) 
were represented in the figure 2. No interference of 
endogenous peaks with the Simvastatin or Lovastatin at 
their respective retention time of Simvastatin was 6.5 
min, Lovastatin was 5.4 min respectively. 
 
 
Figure 2: Blank sample 
4.2 Linearity of calibration curve: 
Linearity of Simvastatin ranging from the concentrations of 0.1 µg/ml to 10 µg/ml was determined. The regression 
equation was y= 0.214x + 0.059 with correlation coefficient r2= 0.992, which shows that the method was linear 
represented in table-1 and figure-3. 
Table 1: Linearity data of Simvastatin 
Conc. (µg/ml) Peak area 
0.1 0.07635 
0.25 0.09882 
0.5 0.1659 
1 0.2949 
2.5 0.592 
5 1.129 
10 2.1977 
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Figure 3: Linearity graph of Simvastatin. 
4.3. LOD and LOQ: 
The LOD and LOQ were calculated using the formula 
and the LOD and LOQ of Simvastatin was found to be 
0.18 µg/ml and 0.54 µg/ml respectively. 
4.4. Precision and Accuracy: 
Intra- day accuracy of 40, 400 and 4000 ng/ml was found 
to be 92.95, 93.75 and 97.77 respectively and inter- day 
accuracy was found to be 89.17, 91.47 and 97.04 
respectively. Therefore, the intra- and inter- day 
precision (% deviation) were within < ±6% for the LOQ. 
The intra- and inter-day assay precision (CV) ranged 
from 4.36 to 1.58 and 5.55 to 2.67 % respectively. These 
results showed in table-2 indicated that the present assay 
has very good accuracy and precision. 
 
Table 2:  Inter- and Intra-day variation of selected samples 
INTRA 
DAY 
Trial 1 Trial 2 Trial 3 MEAN* SD* 
Accuracy 
% 
CV% 
40 37.99 35.32 38.25 37.18 1.62 92.95 4.36 
400 383 377 365 375 9.16 93.75 2.44 
4000 3975.23 3899.19 3852.34 3908.92 62.02 97.77 1.58 
INTER DAY 
40 36.37 33.44 37.22 35.67 1.98 89.17 5.55 
400 377.33 368.11 352.23 365.89 12.69 91.47 3.47 
4000 3985.22 3882.26 3777.2 3881.56 104.01 97.04 2.67 
          *Mean, SD (n = 3) 
 
5. CONCLUSION: 
The HPLC method was developed using Lovastatin as an 
internal standard. The method was cost effective and 
easy method with high resolution and sharp peaks. 
Developed method was validated as per the ICH 
guidelines using specificity, linearity, limit of detection, 
limit of quantification, Precision and accuracy. As the 
developed method was found to be satisfactory and 
complies with all validated parameters, this method can 
be used for evaluation of Simvastatin. 
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